+125% earnings on previous quarter, average growth of +30% previous quarters +76% revenue growth, accelerating from previous quarters +44% net margins, expanding from +30% Positive earnings revisions
125% earnings growth past quarter, +30% previous quarters +76% revenue growth past quarter, accelerating from the precious quarters Positive earnings revisions
Long above box to targets or wait for pull back long at the bottom of box or targets below box.
VRTX retook the 50 MA. Pullback from previous high was in low volume. IBD 50 name. Perfect IBD score of 99. Long @ $271
Hey traders,big upward effort it is possible to see an acceleration on this configuration, unless a change of decision takes place ... Please LIKE & FOLLOW, thank you!
May-11-20 04:31PM How A Gene-Editing Drug Sent This IBD Stock Of The Day To A New High Investor's Business Daily +5.03%
We started to see some consolidation after it had a good earnings reaction. 1st in its industry group with a A+ rating and accelerating earnings with price tightening up. The weekly looks good with a few weeks of consolidation and 10 week MA just under that 275 low. I'll be looking for a buy for a half position through 276 against 267 and scale in my second half...
Short by put option to weekly level support $53
SHORT Short by put option to weekly level support $53
despite the coronavirus pandemic, VRTX biotech is breaking out with volume!
$VRTX has a very similar chart to $LLY can also short the pullback into an inverse as its sitting at its neckline.
VRTX adalah kod bagi syarikat Vertex Pharmaceutical Inc yang diperbuat dari segi sektor kesihatan. Mengikut pemerhatian gelombang sahlun tentang saham ini adalah uptrend@bullish dengan kenaikkan sebanyak 5.92% dalam tempoh 3 bulan lepas. Dari segi Syariah, saham ini adalah Patuh Syariah
VRTX up after exceeding earnings on JAN 30, finds support at 240. 5 day moving average is strong. Double inverted head and shoulders signals strong buy, possible breakout. Entry at 243, target price 252, stop loss 241.